MSC Therapy for ARDS

About StromaBio

StromaBio is a Swedish clinical-stage biotech leveraging over two decades of foundational research to develop allogeneic mesenchymal stromal cell (MSC) therapies. Its platform targets high-need areas in inflammatory and neurodegenerative diseases, specifically ARDS and Alzheimer's Disease. The company is built on a strong IP position and a decade of pre-clinical and clinical data, positioning it to advance two product candidates toward market authorization.

Therapeutic Areas